Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Tao

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Pharmaceutical Design|September 15, 2012
PI3K pathway inhibitors: better not left aloneBen Markman, Jessica J Tao, Maurizio Scaltriti
Breast (Edinburgh, Scotland)|August 25, 2015
Long term side effects of adjuvant chemotherapy in patients with early breast cancerJessica J Tao, Kala Visvanathan, Antonio C Wolff
Annual Review of Medicine|November 10, 2017
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven OncologyJessica J Tao, Alison M Schram, David M Hyman
Plos One|June 19, 2019
Demonstrating the impact of POLST forms on hospital care requires information not contained in state registriesAlison E Turnbull, Xuejuan Ning, Anirudh Rao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Learning All That We Can From MyPathwayJessica J Tao, Alison M Schram, James J Harding, et al.
The Journal of Clinical Endocrinology and Metabolism|August 17, 2006
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testingFrederieke M Brouwers, Graeme Eisenhofer, Jessica J Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid TumorsJessica J Tao, Nicholas A Cangemi, Vicky Makker, et al.
JCO Precision Oncology|February 9, 2022
<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to EntrectinibJessica J Tao, Ge Wei, Roopal Patel, et al.
JCO Precision Oncology|October 11, 2024
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board DiscussionMaria Fatteh, Jaime Wehr, Katerina Karaindrou, et al.
JCO Precision Oncology|July 1, 2026
Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical <i>EGFR</i> Mutation: A Molecular Tumor Board DiscussionIlias Ziakas, Amna Jamali, Michael Conroy, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Design|September 15, 2012
PI3K pathway inhibitors: better not left aloneBen Markman, Jessica J Tao, Maurizio Scaltriti
Breast (Edinburgh, Scotland)|August 25, 2015
Long term side effects of adjuvant chemotherapy in patients with early breast cancerJessica J Tao, Kala Visvanathan, Antonio C Wolff
Annual Review of Medicine|November 10, 2017
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven OncologyJessica J Tao, Alison M Schram, David M Hyman
Plos One|June 19, 2019
Demonstrating the impact of POLST forms on hospital care requires information not contained in state registriesAlison E Turnbull, Xuejuan Ning, Anirudh Rao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Learning All That We Can From MyPathwayJessica J Tao, Alison M Schram, James J Harding, et al.
The Journal of Clinical Endocrinology and Metabolism|August 17, 2006
High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testingFrederieke M Brouwers, Graeme Eisenhofer, Jessica J Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid TumorsJessica J Tao, Nicholas A Cangemi, Vicky Makker, et al.
JCO Precision Oncology|February 9, 2022
<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to EntrectinibJessica J Tao, Ge Wei, Roopal Patel, et al.
JCO Precision Oncology|October 11, 2024
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board DiscussionMaria Fatteh, Jaime Wehr, Katerina Karaindrou, et al.
JCO Precision Oncology|July 1, 2026
Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical <i>EGFR</i> Mutation: A Molecular Tumor Board DiscussionIlias Ziakas, Amna Jamali, Michael Conroy, et al.
Pageof 2